George Church was part of the team that pioneered CRISPR gene editing. In 2021 he co-founded a kind of real-world "Jurassic Park" — Colossal Biosciences, a biotech startup working to de-extinct the Woolly Mammoth. For the 30th anniversary of the movie Jurassic Park, Rolling Stone brought in Colossal's co-founder and CEO, Ben Lamm, to share how the movie inspired and influenced their plans. Lamm writes that in 1993 he was 11 years old when he'd first seen the movie Jurassic Park. And even then, "Yes, as an 11-year-old I thought, what if dinosaurs could be real?" Lamm says he's now excited at "not just de-extincting animals but at the possibility for endless discoveries that would arise from the pursuit of doing so..." When I first told my lawyer that I was interested in starting Colossal and bringing back the woolly mammoth, he asked me if I had read Michael Crichton's book or seen Spielberg's Jurassic Park movie. Since then, it's a question that has come up in nearly every meeting with investors, journalists, and lawyers. I have, which meant that I spent a number of years thinking about if we should de-extinct animals before I set out to figure out if we could. (Thanks, Dr. Ian Malcolm.) Before ever setting foot in a lab, I spent many years and countless hours thinking about the moral questions at the heart of the story. And, with each successive year, I watched, heard, and learned about more and more animals dying due to climate change — a modern-day extinction. I came to the conclusion that the question is no longer should we practice de-extinction science but how long do we have to get it right... [T]he scary vision of the future isn't one where dinosaurs escape Isla Nubar and fly to the mainland, putting a healthy planet at risk, but instead a future where there aren't enough animals left to support food webs and ecosystems. And that includes humans, too... [I]t is our belief that it is possible to safeguard against or even stop that fatalist future vision using a similar approach in the original movie with some slight variations. It all goes back to genetics and a lot of what I learned about when I first met George... In the same way that wireless headsets, CAT scans, LEDs, the computer mouse, and thermal blankets are all products of going to the moon, de-extinction efforts have created breakthroughs already for both conservation and human healthcare. In Colossal's first few years of work, our woolly mammoth research alone has not only accelerated genetic rescue in elephants, but also, it is working to cure a deadly elephant virus that kills 25% of all baby elephants worldwide each year. The de-extinction toolkit is also establishing a genetic backup of all living elephant species, and building the necessary tools for elephant cloning and gestation. And now, unlike Dr. Hammond, who bought an island and hid his experiment from the world, governments are coming to us asking if we can help them to restore their critically endangered animals and help safeguard their keystone species. Lamm points out that you can get good DNA samples from specimens frozen in permafrost, skeletons preserved in caves, and from preserved specimens in museums. But "You can't get DNA from amber. Trust us. It's porous and doesn't preserve well."

Read more of this story at Slashdot.

3M will pay $10.3 billion to settle lawsuits over contamination of drinking water with PFAS, a class of chemicals known as "forever chemicals" that have been linked to health problems. NPR reports: The deal would compensate water providers for pollution with per- and polyfluorinated substances, known collectively as PFAS -- a broad class of chemicals used in nonstick, water- and grease-resistant products such as clothing and cookware. Described as "forever chemicals" because they don't degrade naturally in the environment, PFAS have been linked to a variety of health problems, including liver and immune-system damage and some cancers. The compounds have been detected at varying levels in drinking water around the nation. The Environmental Protection Agency in March proposed strict limits on two common types, PFOA and PFOS, and said it wanted to regulate four others. Water providers would be responsible for monitoring their systems for the chemicals. The agreement would settle a case that was scheduled for trial earlier this month involving a claim by Stuart, Florida, one of about 300 communities that have filed similar suits against companies that produced firefighting foam or the PFAS it contained. 3M chairman Mike Roman said the deal was "an important step forward" that builds on the company's decision in 2020 to phase out PFOA and PFOS and its investments in "state-of-the-art water filtration technology in our chemical manufacturing operations." The company, based in St. Paul, Minnesota, will halt all PFAS production by the end of 2025, he said. The settlement will be paid over 13 years and could reach as high as $12.5 billion, depending on how many public water systems detect PFAS during testing that EPA has required in the next three years, said Dallas-based attorney Scott Summy, one of the lead attorneys for those suing 3M and other manufacturers. The payment will help cover costs of filtering PFAS from systems where it's been detected and testing others, he said.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Associated Press: For the first time, U.S. regulators on Wednesday approved the sale of chicken made from animal cells, allowing two California companies to offer "lab-grown" meat to the nation's restaurant tables and eventually, supermarket shelves. The Agriculture Department gave the green light to Upside Foods and Good Meat, firms that had been racing to be the first in the U.S. to sell meat that doesn't come from slaughtered animals -- what's now being referred to as "cell-cultivated" or "cultured" meat as it emerges from the laboratory and arrives on dinner plates. The companies received approvals for federal inspections required to sell meat and poultry in the U.S. The action came months after the U.S. Food and Drug Administration deemed that products from both companies are safe to eat. A manufacturing company called Joinn Biologics, which works with Good Meat, was also cleared to make the products. Cultivated meat is grown in steel tanks, using cells that come from a living animal, a fertilized egg or a special bank of stored cells. In Upside's case, it comes out in large sheets that are then formed into shapes like chicken cutlets and sausages. Good Meat, which already sells cultivated meat in Singapore, the first country to allow it, turns masses of chicken cells into cutlets, nuggets, shredded meat and satays. But don't look for this novel meat in U.S. grocery stores anytime soon. Cultivated chicken is much more expensive than meat from whole, farmed birds and cannot yet be produced on the scale of traditional meat, said Ricardo San Martin, director of the Alt:Meat Lab at University of California Berkeley. The companies plan to serve the new food first in exclusive restaurants: Upside has partnered with a San Francisco restaurant called Bar Crenn, while Good Meat dishes will be served at a Washington, D.C., restaurant run by chef and owner Jose Andres.

Read more of this story at Slashdot.

An anonymous reader quotes a report from CBS News: A biotechnology company selling a $949 blood test that it bills as a "first of its kind" to detect cancer said it incorrectly informed about 400 customers that they might have the disease. The Menlo Park, California, company, called Grail, said it sent a form letter to some customers who had bought its Galleri test, which detects a marker for more than 50 types of cancer, "stating incorrectly that a cancer signal was detected," a company spokeswoman told CBS MoneyWatch in a statement. The company blamed a vendor, PWN Health, for the error, citing a "software configuration issue." In a statement, PWN Health said it said the problem was due to "a misconfiguration of our patient engagement platform used to send templated communications to individuals." It added that it has added processes to make sure such a mistake doesn't occur again, and started contacting the people who received the erroneous letters within 36 hours. The error comes amid an increased demand for health care screening tests, especially for chronic diseases such as cancer. Grail is billing its service as a complement to routine single-cancer tests for diseases such as colon or breast cancer, and said that the blood test can detect forms of the disease that aren't routinely screened for, such as in the gallbladder and pancreas. Grail said it hasn't received reports of patient harm or "adverse events" due to the erroneous letters. "After being notified of the incident, Grail immediately began outreach by phone or email to all individuals who received the PWNHealth letter, and we continued our efforts until we confirmed we successfully reached each individual via phone, email or letter," the spokeswoman said. "The issue was in no way related to or caused by an incorrect Galleri laboratory test result." More than half the erroneous letters were sent to customers who hadn't had their blood drawn yet for the Galleri test, the spokeswoman added. On Monday, Illumina filed an appeal against a FTC order, "demanding that it divest cancer diagnostic test maker Grail over competition concerns in the U.S. market for cancer tests," reports Reuters. According to the filing, Illumina is arguing that the FTC "violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal."

Read more of this story at Slashdot.

Disgraced Theranos founder Elizabeth Holmes has begun her 11-year prison sentence after being convicted of four counts of fraud. The BBC reports: She will serve her term in a minimum-security prison in Texas. Holmes reported to the federal facility in Bryan, Texas, which holds between 500 and 700 inmates at any given time, on Tuesday. It is about 100 miles (160km) north of Houston, her hometown. Her arrival at the facility was confirmed by the Federal Bureau of Prisons, which declined to give any more details about her confinement, citing privacy concerns. There, the woman once billed as the world's youngest self-made billionaire might work alongside other inmates for between 12 cents (10p) and $1.15 (93p) an hour - much of which will go towards her court-mandated restitution payments. [...] The Texas prison camp where Holmes will serve time is a sprawling 37-acre facility. Most inmates there have been convicted of non-violent crimes, low-level drug dealing or white-collar offenses. According to the facility's handbook, life largely revolves around work and extracurricular activities that include foreign language, computer literacy or business courses. Holmes had fought to stay out of prison while her legal appeal works its way through the courts. She argued a delay would allow her to raise "substantial questions" about the case that could warrant a new trial. Her defense team also argued that she should remain free to care for her children, one who is nearly two and the other three months old. The Wall Street Journal reported the prison has facilities where inmates can host gatherings and where children can play. Holmes and other mothers are allowed to hold their children in their lap and breastfeed their infants, according to official Bureau of Prison guidelines.

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: Last spring, engineers in Barcelona packed up the sperm-injecting robot they'd designed and sent it by DHL to New York City. They followed it to a clinic there, called New Hope Fertility Center, where they put the instrument back together, assembling a microscope, a mechanized needle, a tiny petri dish, and a laptop. Then one of the engineers, with no real experience in fertility medicine, used a Sony PlayStation 5 controller to position a robotic needle. Eyeing a human egg through a camera, it then moved forward on its own, penetrating the egg and dropping off a single sperm cell. Altogether, the robot was used to fertilize more than a dozen eggs. The result of the procedures, say the researchers, were healthy embryos—and now two baby girls, who they claim are the first people born after fertilization by a "robot." The startup company that developed the robot, Overture Life, says its device is an initial step toward automating in vitro fertilization, or IVF, and potentially making the procedure less expensive and far more common than it is today. Right now, IVF labs are multimillion-dollar affairs staffed by trained embryologists who earn upwards of $125,000 a year to delicately handle sperm and eggs using ultra-thin hollow needles under a microscope. But some startups say the entire process could be carried out automatically, or nearly so. Overture, for instance, has filed a patent application describing a "biochip" for an IVF lab in miniature, complete with hidden reservoirs containing growth fluids, and tiny channels for sperm to wiggle through. "Think of a box where sperm and eggs go in, and an embryo comes out five days later," says Santiago Munne, the prize-winning geneticist who is chief innovation officer at the Spanish company. He believes that if IVF could be carried out inside a desktop instrument, patients might never need to visit a specialized clinic, where a single attempt at getting pregnant can cost $20,000 in the US. Instead, he says, a patient's eggs might be fed directly into an automated fertility system at a gynecologist's office. "It has to be cheaper. And if any doctor could do it, it would be," says Munne.

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: Embryos made from stem cells -- instead of a sperm and egg -- have been created from monkey cells for the first time. When researchers put these "synthetic embryos" into the uteruses of adult monkeys, some showed the initial signs of pregnancy. It's the furthest scientists have ever been able to take lab-grown embryos in primates -- and the work hints that it may one day be possible to generate fetuses this way. The team behind the research, Zhen Liu at the Chinese Academy of Sciences in Shanghai and his colleagues, started with embryonic stem cells originally taken from macaque monkey embryos. These cells have been grown in labs for multiple generations and, given the right conditions, have the potential to develop into pretty much any type of body cell, including those that make up organs, blood, and nervous system. The team used a set of lab conditions, which they tweaked and improved, to encourage embryonic stem cells to develop further. Over several days, the cells began developing in a very similar way to embryos. The resulting blobs of cells are called blastoids, because they look like early embryos, which are called blastocysts. After the blastoids had been growing in a dish for seven days, the researchers put them through a series of tests to figure out how similar they were to typical embryos. In one test, the team separated the individual cells in the blastoids and checked to see which genes were expressed in each one. The team analyzed over 6,000 individual cells this way. These tests revealed close similarities between the stem-cell-derived embryos and conventional monkey embryos. Some of the blastoids were grown for longer -- up to 17 days. These structures looked very much like typical embryos, the researchers say, although other scientists not involved in the study say more evidence is needed to prove just how similar they are. The only way to find out how embryo-like these blastoids really are is to test whether they can develop in a monkey's uterus. So the team put between eight and 10 seven-day-old blastoids into the uteruses of each of eight adult monkeys. The researchers then monitored the transferred blastoids for three weeks. The researchers believe that in three of these monkeys, the blastoids successfully implanted in the uterus and appeared to generate a yolk sac -- one of the very first signs of pregnancy. These monkeys also had elevated levels of pregnancy hormones. In other words, they would have had a positive pregnancy test. But within 20 days of transfer, the monkey blastoids stopped developing and seemed to come apart, say Liu and colleagues, who published their results in the journal Cell Stem Cell. The results suggest that blastoids still aren't perfect replicas of normal embryos. "That might be because a typical embryo is generated from an egg, which is then fertilized by sperm," reports MIT Technology Review. "A blastoid made from stem cells might express genes in the same way as a normal embryo, but it may be missing something crucial that normally comes from an egg." "There's also a chance that the team might have seen more progress if the experiment had been done in more monkeys. After all, of the 484 blastoids that were developing at day seven, only five survived to day 17."

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Guardian: A mammoth meatball has been created by a cultivated meat company, resurrecting the flesh of the long-extinct animals. The project aims to demonstrate the potential of meat grown from cells, without the slaughter of animals, and to highlight the link between large-scale livestock production and the destruction of wildlife and the climate crisis. The mammoth meatball was produced by Vow, an Australian company, which is taking a different approach to cultured meat. There are scores of companies working on replacements for conventional meat, such as chicken, pork and beef. But Vow is aiming to mix and match cells from unconventional species to create new kinds of meat. The company has already investigated the potential of more than 50 species, including alpaca, buffalo, crocodile, kangaroo, peacocks and different types of fish. The first cultivated meat to be sold to diners will be Japanese quail, which the company expects will be in restaurants in Singapore this year. [...] Vow worked with Prof Ernst Wolvetang, at the Australian Institute for Bioengineering at the University of Queensland, to create the mammoth muscle protein. His team took the DNA sequence for mammoth myoglobin, a key muscle protein in giving meat its flavor, and filled in the few gaps using elephant DNA. This sequence was placed in myoblast stem cells from a sheep, which replicated to grow to the 20 billion cells subsequently used by the company to grow the mammoth meat. "It was ridiculously easy and fast," said Wolvetang. "We did this in a couple of weeks." Initially, the idea was to produce dodo meat, he said, but the DNA sequences needed do not exist. Tim Noakesmith, cofounder of Vow, said: "We chose the woolly mammoth because it's a symbol of diversity loss and a symbol of climate change." Bas Korsten at creative agency Wunderman Thompson added: "Our aim is to start a conversation about how we eat, and what the future alternatives can look and taste like. Cultured meat is meat, but not as we know it." No one has yet to taste the mammoth meatball, notes the report. "We haven't seen this protein for thousands of years," said Wolvetang. "So we have no idea how our immune system would react when we eat it. But if we did it again, we could certainly do it in a way that would make it more palatable to regulatory bodies."

Read more of this story at Slashdot.

An anonymous reader quotes a report from CBS News: The Food and Drug Administration on Monday cleared cultured "cultured chicken cell material" made by GOOD Meat as safe for use as human food. While the FDA said the lab-grown chicken was safe to eat, GOOD Meat still needs approval from the Agriculture Department before i can sell the product in the U.S. If approved, acclaimed chef Jose Andres plans to serve GOOD Meat's chicken to customers at his Washington, D.C. restaurant. He's on GOOD Meat's board of directors. The FDA previously gave the green light to lab-grown chicken made by Upside Foods in November. Upside Foods and GOOD Meat both use cells from chickens to create the cultured chicken products. Once cells are extracted, GOOD Meat picks the cells most likely to produce healthy, sustainable and tasty meat, the company explained. The cells are immersed in nutrients inside a tank. They grow and divide, creating the cultured chicken, which can be harvested after four to six weeks. GOOD Meat's chicken is already sold in Singapore. "Today's news is more than just another regulatory decision -- it's food system transformation in action," says Bruce Friedrich, president and founder of the Good Food Institute, a non-profit think tank that focuses on alternatives to traditional meat production. "Consumers and future generations deserve the foods they love made more sustainably and in ways that benefit the public good -- ways that preserve our land and water, ways that protect our climate and global health," Friedrich says.

Read more of this story at Slashdot.

MIT Technology Review has revealed two cases in which babies conceived with the three-parent baby technique have shown what scientists call "reversion." "In both cases, the proportion of mitochondrial genes from the child's mother has increased over time, from less than 1% in both embyros to around 50% in one baby and 72% in another," they report. From the report: When the first baby born using a controversial procedure that meant he had three genetic parents was born back in 2016, it made headlines. The baby boy inherited most of his DNA from his mother and father, but he also had a tiny amount from a third person. The idea was to avoid having the baby inherit a fatal illness. His mother carried genes for a disease in her mitochondria. Swapping these with genes from a donor -- a third genetic parent -- could prevent the baby from developing it. The strategy seemed to work. Now clinics in other countries, including the UK, Greece, and Ukraine, are offering the same treatment. It was made legal in Australia last year. But it might not always be successful. [...] Fortunately, both babies were born to parents without genes for mitochondrial disease; they were using the technique to treat infertility. But the scientists behind the work believe that around one in five babies born using the three-parent technique could eventually inherit high levels of their mothers' mitochondrial genes. For babies born to people with disease-causing mutations, this could spell disaster -- leaving them with devastating and potentially fatal illness. The findings are making some clinics reconsider the use of the technology for mitochondrial diseases, at least until they understand why reversion is happening. "These mitochondrial diseases have devastating consequences," says Bjorn Heindryckx at Ghent University in Belgium, who has been exploring the treatment for years. "We should not continue with this." "It's dangerous to offer this procedure [for mitochondrial diseases]," says Pavlo Mazur, an embryologist based in Kyiv, Ukraine, who has seen one of these cases firsthand.

Read more of this story at Slashdot.

According to Reuters, Elon Musk's medical device company, Neuralink, was denied permission last year to begin human trials of a revolutionary brain implant to treat intractable conditions such as paralysis and blindness. The U.S. Food and Drug Administration (FDA) outlined dozens of issues the company must address before human testing can begin, according to seven current and former employees. From the report: The agency's major safety concerns involved the device's lithium battery; the potential for the implant's tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue, the employees said. A year after the rejection, Neuralink is still working through the agency's concerns. Three staffers said they were skeptical the company could quickly resolve the issues -- despite Musk's latest prediction at a Nov. 30 presentation that the company would secure FDA human-trial approval this spring. Neuralink has not disclosed details of its trial application, the FDA's rejection or the extent of the agency's concerns. As a private company, it is not required to disclose such regulatory interactions to investors. During the hours-long November presentation, Musk said the company had submitted "most of our paperwork" to the agency, without specifying any formal application, and Neuralink officials acknowledged the FDA had asked safety questions in what they characterized as an ongoing conversation. Such FDA rejections do not mean a company will ultimately fail to gain the agency's human-testing approval. But the agency's pushback signals substantial concerns, according to more than a dozen experts in FDA device-approval processes. The rejection also raises the stakes and the difficulty of the company's subsequent requests for trial approval, the experts said. The FDA says it has approved about two-thirds of all human-trial applications for devices on the first attempt over the past three years. That total rose to 85% of all requests after a second review. But firms often give up after three attempts to resolve FDA concerns rather than invest more time and money in expensive research, several of the experts said. Companies that do secure human-testing approval typically conduct at least two rounds of trials before applying for FDA approval to commercially market a device.

Read more of this story at Slashdot.

Three long-time Slashdot readers all submitted this story — schwit1, sinij, and DevNull127. DevNull127 writes: Four U.S. agencies have concluded that the Covid-19 virus originated at the Wuhan market, the Wall Street Journal reports. The U.S. National Intelligence Council reached the same conclusion. Then there's two more agencies (including America's CIA) that are "undecided." But there is one agency that decided — with "low confidence" — that the virus had somehow leaked from a lab. (And the FBI also decided with "moderate confidence" on that same theory.) "The new report highlights how different parts of the intelligence community have arrived at disparate judgments about the pandemic's origin," writes the Wall Street Journal — adding that unfortunately U.S. officials "declined" to give any details on what led to the Energy Department's position. The Wall Street Journal also notes: Despite the agencies' differing analyses, the update reaffirmed an existing consensus between them that Covid-19 wasn't the result of a Chinese biological-weapons program, the people who have read the classified report said.... Some scientists argue that the virus probably emerged naturally and leapt from an animal to a human, the same pathway for outbreaks of previously unknown pathogens. Intelligence analysts who have supported that view give weight to "the precedent of past novel infectious disease outbreaks having zoonotic origins," the flourishing trade in a diverse set of animals that are susceptible to such infections, and their conclusion that Chinese officials didn't have foreknowledge of the virus, the 2021 report said. Also responding to the Department of Energy's outlying position was a virologist at the Vaccine and Infectious Disease Organization at Canada's University of Saskatchewan, who posted a series of observations on Twitter: The available evidence shows overwhelmingly that the pandemic started at Huanan market via zoonosis. I have no idea what this evidence that Department of Energy has is. All I know that it is "weak" and resulted in a conclusion of "low confidence". It reportedly comes from the DOE's own network of national labs rather than through spying. But I do know that to be consistent with the available scientific evidence, the DOE has to explain how the virus emerged twice over 2 wks in humans at the same market the size of a tennis court, over 8 km & across a river from the only lab in Wuhan working on SARSr-CoVs.... Claims of a progenitor at WIV are pure speculation & unsupported by evidence.... Despite 3 years of a global search for this evidence, it has not materialized, while evidence supporting zoonosis associated with Huanan has continued to stack up. At some point, an absence of evidence might just be evidence of absence.

Read more of this story at Slashdot.

Researchers at Linkoping, Lund and Gothenburg universities in Sweden have successfully grown electrodes in living tissue using the body's molecules as triggers. The result, published in the journal Science, paves the way for the formation of fully integrated electronic circuits in living organisms. Phys.Org reports: Linking electronics to biological tissue is important to understanding complex biological functions, combating diseases in the brain, and developing future interfaces between man and machine. However, conventional bioelectronics, developed in parallel with the semiconductor industry, have a fixed and static design that is difficult, if not impossible, to combine with living biological signal systems. To bridge this gap between biology and technology, researchers have developed a method for creating soft, substrate-free, electronically conductive materials in living tissue. By injecting a gel containing enzymes as the "assembly molecules," the researchers were able to grow electrodes in the tissue of zebrafish and medicinal leeches. "Contact with the body's substances changes the structure of the gel and makes it electrically conductive, which it isn't before injection. Depending on the tissue, we can also adjust the composition of the gel to get the electrical process going," says Xenofon Strakosas, researcher at LOE and Lund University and one of the study's main authors. The body's endogenous molecules are enough to trigger the formation of electrodes. There is no need for genetic modification or external signals, such as light or electrical energy, which has been necessary in previous experiments. The Swedish researchers are the first in the world to succeed in this. In their study, the researchers further show that the method can target the electronically conducting material to specific biological substructures and thereby create suitable interfaces for nerve stimulation. In the long term, the fabrication of fully integrated electronic circuits in living organisms may be possible. In experiments conducted at Lund University, the team successfully achieved electrode formation in the brain, heart, and tail fins of zebrafish and around the nervous tissue of medicinal leeches. The animals were not harmed by the injected gel and were otherwise not affected by the electrode formation. One of the many challenges in these trials was to take the animals' immune system into account.

Read more of this story at Slashdot.

The Guardian reports: Scientists have pinpointed pieces of DNA which, they say, act like Bond villains in the way they help cancers spread. These microscopic agents have also been shown to be responsible for helping tumours gain resistance to anti-cancer drugs. The discovery of these bits of genetic material — known as extrachromosomal DNA or ecDNA — could revolutionise the treatments of some of the most aggressive tumours that affect people today, add the researchers.... Made up of tiny loops of DNA, these genetic villains survive outside the chromosomes which are our cells' main repositories of genetic material.... "We have found that ecDNA act as cancer-causing genes that have somehow separated themselves from a person's chromosomes and have started to behave in ways that circumvent the normal rules of genetics," said Stanford university geneticist Howard Chang. "They behave like villains in a Bond film. At first, in a film, you see different explosions, killings and disasters occurring and you don't know why they are happening or who is responsible. Then, at some point, you finally meet the villain who is revealed to be the agent of all this mayhem." They also seem to resemble the Bond henchman who re-appears at the end of the movie. Professor Paul Mischel of California's Stanford University says that when treating the most aggressive cancers, "The vulnerable gene had quickly disappeared when threatened by cancer drugs and was hidden in ecDNA. Then it reappeared once it was safe for it to start causing damage again." Mischel calls the discovery "a gamechanger," identifying the culprit "responsible for a large number of the more advanced, most serious cancers affecting people today. If we can block their activities, we can block the spread of these cancers." And that hope was echoed by Dr Mariam Jamal-Hanjani of University College London Cancer Institute "The crucial point is that once we have found the cause of the problem then it becomes possible to develop and try out all sorts of drugs and therapies to tackle that." * "The discovery of how these bits of DNA behave inside our bodies is a gamechanger," said Professor Paul Mischel of California's Stanford university, one of the leaders of the programme. "We believe they are responsible for a large number of the more advanced, most serious cancers affecting people today. If we can block their activities, we can block the spread of these cancers."

Read more of this story at Slashdot.

Genetically modified seedlings from biotechnology company Living Carbon have been planted in a low-lying tract of southern Georgia's pine belt. According to a paper that has yet to be peer reviewed, these trees are engineered to grow 50 percent faster than non-modified ones over five months in the greenhouse. The New York Times reports: The poplars may be the first genetically modified trees planted in the United States outside of a research trial or a commercial fruit orchard. Just as the introduction of the Flavr Savr tomato in 1994 introduced a new industry of genetically modified food crops, the tree planters on Monday hope to transform forestry. Living Carbon, a San Francisco-based biotechnology company that produced the poplars, intends for its trees to be a large-scale solution to climate change. "We've had people tell us it's impossible," Maddie Hall, the company's co-founder and chief executive, said of her dream to deploy genetic engineering on behalf of the climate. But she and her colleagues have also found believers -- enough to invest $36 million in the four-year-old company. The company's researchers created the greenhouse-tested trees using a bacterium that splices foreign DNA into another organism's genome. But for the trees they planted in Georgia, they turned to an older and cruder technique known as the gene gun method, which essentially blasts foreign genes into the trees' chromosomes. In a field accustomed to glacial progress and heavy regulation, Living Carbon has moved fast and freely. The gene gun-modified poplars avoided a set of federal regulations of genetically modified organisms that can stall biotech projects for years. (Those regulations have since been revised.) By contrast, a team of scientists who genetically engineered a blight-resistant chestnut tree using the same bacterium method employed earlier by Living Carbon have been awaiting a decision since 2020. [...] In contrast to fast-growing pines, hardwoods that grow in bottomlands like these produce wood so slowly that a landowner might get only one harvest in a lifetime, said [Vince Stanley, a seventh-generation farmer who manages more than 25,000 forested acres in Georgia's pine belt]. He hopes Living Carbon's "elite seedlings" will allow him to grow bottomland trees and make money faster. "We're taking a timber rotation of 50 to 60 years and we're cutting that in half," he said. "It's totally a win-win." [...] The U.S. Forest Service, which plants large numbers of trees every year, has said little about whether it would use engineered trees. To be considered for planting in national forests, which make up nearly a fifth of U.S. forestland, Living Carbon's trees would need to align with existing management plans that typically prioritize forest health and diversity over reducing the amount of atmospheric carbon, said Dana Nelson, a geneticist with the service. "I find it hard to imagine that it would be a good fit on a national forest," Dr. Nelson said. Living Carbon is focusing for now on private land, where it will face fewer hurdles. Later this spring it will plant poplars on abandoned coal mines in Pennsylvania. By next year Ms. Hall and Mr. Mellor hope to be putting millions of trees in the ground. The report notes that the modified trees are all female, "so they won't produce pollen." "They're also being planted alongside native trees like sweet gum, tulip trees and bald cypress, to avoid genetically identical stands of trees known as monocultures; non-engineered poplars are being planted as experimental controls."

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: Imagine that you were provided no-cost fertility treatment and also offered a free DNA test to gauge which of those little IVF embryos floating in a dish stood the best chance of getting into a top college someday. Would you have the test performed? If you said yes, you're among about 40% percent of Americans who told pollsters they'd be more likely than not to test and pick IVF embryos for intellectual aptitude, despite hand-wringing by ethicists and gene scientists who think it's a bad idea. The opinion survey, published in the journal Science, was carried out by economists and other researchers who say surprisingly strong support for the embryo tests means the US might need to hurry up and set policies for the technology. The new poll compared people's willingness to advance their children's prospects in three ways: using SAT prep courses, embryo tests, and gene editing on embryos. It found some support even for the most radical option, genetic modification of children, which is prohibited in the US and many other countries. About 28% of those polled said they'd probably do that if it was safe. The authors of the new poll are wrestling with the consequences of information that they helped discover via a series of ever larger studies to locate genetic causes of human social and cognitive traits, including sexual orientation and intelligence. That includes a report published last year on how the DNA differences among more than 3 million people related to how far they'd gone in school, a life result that is correlated with a person's intelligence. The result of such research is a so-called "polygenic score," or a genetic test that can predict from genes whether -- among other things -- someone is going to be more or less likely to attend college. Of course, environmental factors matter plenty, and DNA is not destiny. Yet the gene tests are surprisingly predictive. In their poll, the researchers told people to assume that around 3% of kids will go to a top-100 college. By picking the one of 10 IVF embryos with the highest gene score, parents would increase that chance to 5% for their kid. It's tempting to dismiss the advantage gained as negligible, but "assuming they are right," Carmi says, it's actually "a very large relative increase" in the chance of going to such a school for the offspring in question -- about 67%. "The current poll found only 6% of people are morally opposed to IVF today, only about 17% have strong moral qualms about testing embryos, and 38% would probably do to boost education prospects if given the opportunity," adds the report.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Gizmodo: Genetic engineering company Colossal Biosciences said Tuesday that it will try to resurrect the extinct dodo bird, and it's received $150 million in new funding to support its "de-extinction" activities. The dodo was already part of Colossal's plans by September 2022, but now the company has announced it with all the pomp, circumstance, and seed funding that suggests it will actually go after that goal. The $150 million, the company's second round of funding, was led by several venture capital firms, including United States Innovative Technology Fund and In-Q-Tel, a VC firm funded by the CIA that first put money into the company in September. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial. Colossal's stated goal is not to simply bring these creatures back for vibes; its contention is that reintroducing the species to their respective habitats would help restore a certain amount of normalcy to those environments. Mammoths died out about 4,000 years ago on Wrangel Island, off the northeastern coast of Russia. The dodo, a species of flightless bird native to the island of Mauritius, was gone by 1681. The last known thylacine died at a zoo in Tasmania in 1936. Scientists have sequenced the genomes of all three species -- the mammoth's in 2015, the dodo's in 2016, and the thylacine's in 2018. The latter species were driven to extinction by humankind; humans hunted the dodo, introduced predators and pests to its environment, and contributed to its habitat loss. Humans may have played a role in mammoth extinction as well, but the dodo and the thylacine are classic examples of our ability to wipe out species at extraordinary speed. [...] If the company's work pans out -- and that's a big if -- proxy species of those extinct animals will be brought to bear. That's because the genetically engineered animals produced by Colossal would not be a bonafide mammoth, dodo, or thylacine. In 2016, the International Union for Conservation of Nature's Species Survival Commission published a report (PDF) denoting ground rules for creating proxy species. "Proxy is used here to mean a substitute that would represent in some sense (e.g. phenotypically, behaviorally, ecologically) another entity -- the extinct form," the commission stated, adding that "Proxy is preferred to facsimile, which implies creation of an exact copy." De-extinction is something of a misnomer, as this process, if successful, will yield science's best analogue for an extinct creature, not the creature itself as it existed in the past. De-extinction methods generally rely on using a living creature's genetics in the resurrection process. That means any 21st-century mammoth will have at least some modern elephant DNA imbued in it, and any nascent thylacine would be produced from the genome and egg of a related species.

Read more of this story at Slashdot.

Impossible Foods, which makes plant-based nuggets, burgers and patties, is reportedly laying off 20% of its staff, Bloomberg reported first. TechCrunch reports: According to the story, the 12-year-old company currently employs about 700 workers, which could then affect over 100 employees. This comes as the company made a 6% reduction in its workforce last October. While we know layoffs can happen anytime, it seems like the company was doing well. Earlier this month, the Redwood City, California-based company reported a year of record sales that included over 50% dollar sales growth in 2022. The company also touted that its Impossible Beef product was "the best-selling product by volume of any plant-based meat brand in the U.S." Months before that, CEO Peter McGuinness said in an interview with Bloomberg Technology that the company had a strong balance sheet, good cash flow and growth of between 65% to 70%. In total, Impossible raised $1.9 billion in venture capital, according to Crunchbase data. The last time the company raised capital was a $500 million Series H round in November 2021, and it was at that time that the company was valued at $7 billion. [...] Impossible is not the only plant-based meat alternative company to make layoffs in recent months. In a regulatory filing made last October, Beyond Meat said it planned to lay off about 200 employees, or 19% of its workforce, as part of cost-saving measures as sales were slumping.

Read more of this story at Slashdot.

The New York Times looks at the AbbVie's anti-inflammatory drug Humira and their "savvy but legal exploitation of the U.S. patent system." Though AbbVie's patent was supposed to expire in 2016, since then it's maintained a monopoly that generated $114 billion in revenue by using "a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year." AbbVie did not invent these patent-prolonging strategies; companies like Bristol Myers Squibb and AstraZeneca have deployed similar tactics to maximize profits on drugs for the treatment of cancer, anxiety and heartburn. But AbbVie's success with Humira stands out even in an industry adept at manipulating the U.S. intellectual-property regime.... AbbVie and its affiliates have applied for 311 patents, of which 165 have been granted, related to Humira, according to the Initiative for Medicines, Access and Knowledge, which tracks drug patents. A vast majority were filed after Humira was on the market. Some of Humira's patents covered innovations that benefited patients, like a formulation of the drug that reduced the pain from injections. But many of them simply elaborated on previous patents. For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a type of arthritis that causes inflammation in the joints, among other diseases. In 2014, AbbVie applied for another patent for a method of treating ankylosing spondylitis with a specific dosing of 40 milligrams of Humira. The application was approved, adding 11 years of patent protection beyond 2016. AbbVie has been aggressive about suing rivals that have tried to introduce biosimilar versions of Humira. In 2016, with Amgen's copycat product on the verge of winning regulatory approval, AbbVie sued Amgen, alleging that it was violating 10 of its patents. Amgen argued that most of AbbVie's patents were invalid, but the two sides reached a settlement in which Amgen agreed not to begin selling its drug until 2023. Over the next five years, AbbVie reached similar settlements with nine other manufacturers seeking to launch their own versions of Humira. All of them agreed to delay their market entry until 2023. A drug pricing expert at Washington University in St. Louis tells the New York Times that AbbVie and its strategy with Humira "showed other companies what it was possible to do." But the article concludes that last year such tactics "became a rallying cry" for U.S. lawmakers "as they successfully pushed for Medicare to have greater control over the price of widely used drugs that, like Humira, have been on the market for many years but still lack competition."

Read more of this story at Slashdot.

An anonymous reader quotes a report from MIT Technology Review: Eight years ago, a patient lost her power of speech because of ALS, or Lou Gehrig's disease, which causes progressive paralysis. She can still make sounds, but her words have become unintelligible, leaving her reliant on a writing board or iPad to communicate. Now, after volunteering to receive a brain implant, the woman has been able to rapidly communicate phrases like "I don't own my home" and "It's just tough" at a rate approaching normal speech. That is the claim in a paper published over the weekend on the website bioRxiv by a team at Stanford University. The study has not been formally reviewed by other researchers. The scientists say their volunteer, identified only as "subject T12," smashed previous records by using the brain-reading implant to communicate at a rate of 62 words a minute, three times the previous best. [...] People without speech deficits typically talk at a rate of about 160 words a minute. Even in an era of keyboards, thumb-typing, emojis, and internet abbreviations, speech remains the fastest form of human-to-human communication. The brain-computer interfaces that [co-lead author Krishna Sehnoy's] team works with involve a small pad of sharp electrodes embedded in a person's motor cortex, the brain region most involved in movement. This allows researchers to record activity from a few dozen neurons at once and find patterns that reflect what motions someone is thinking of, even if the person is paralyzed. In previous work, paralyzed volunteers have been asked to imagine making hand movements. By "decoding" their neural signals in real time, implants have let them steer a cursor around a screen, pick out letters on a virtual keyboard, play video games, or even control a robotic arm. In the new research, the Stanford team wanted to know if neurons in the motor cortex contained useful information about speech movements, too. That is, could they detect how "subject T12" was trying to move her mouth, tongue, and vocal cords as she attempted to talk? These are small, subtle movements, and according to Sabes, one big discovery is that just a few neurons contained enough information to let a computer program predict, with good accuracy, what words the patient was trying to say. That information was conveyed by Shenoy's team to a computer screen, where the patient's words appeared as they were spoken by the computer. [...] The current system already uses a couple of types of machine learning programs. To improve its accuracy, the Stanford team employed software that predicts what word typically comes next in a sentence. "I" is more often followed by "am" than "ham," even though these words sound similar and could produce similar patterns in someone's brain. Adding the word prediction system increased how quickly the subject could speak without mistakes.

Read more of this story at Slashdot.